{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:16:51Z","timestamp":1787008611907,"version":"build-2736575974"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A Stability indicating revered phase high performance liquid chromatography (RP-HPLC) method have been developed and validated for the estimation of Mifepristone. LC\u2013MS Studies was carried out for identification of possible degradation products. A simple, rapid, accurate and precise stability indicating RP-HPLC method was developed for quantification of Mifepristone. The developed method used the mixture of methanol and water (88:12\u00a0v\/v) as mobile phase at flow rate of 1\u00a0ml \/min, which was optimized with the help of Quality by Design approach. Detection was carried out at 305\u00a0mm. The linearity of the proposed method was found in the concentration range of 5\u201325\u00a0\u03bcg\/ml with regression coefficient (R2) of 0.996. LOD and LOQ were found to be 0.0324 and 0.0982\u00a0\u03bcg\/ml, respectively. The recovery of the proposed method was found to be 98%\u2013100%. The method was found to be precise and robust. The developed stability indicating RP-HPLC method was successfully applied for quantification of Mifepristone in pharmaceutical dosage form. The degradation products were characterized by LC\u2013MS and the fragmentation pathways were proposed.<\/jats:p>","DOI":"10.1093\/chromsci\/bmaf017","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:15:24Z","timestamp":1743495324000},"source":"Crossref","is-referenced-by-count":3,"title":["Stability Indicating RP-HPLC Method by QbD Approach and LC\u2013MS Characterization of Degradation Products of Mifepristone"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-0664","authenticated-orcid":false,"given":"Chandni","family":"Chandarana","sequence":"first","affiliation":[{"name":"Department of Quality Assurance , , Silvassa ,","place":["India"]},{"name":"SSR College of Pharmacy Sayli , , Silvassa ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isha","family":"Juwarwala","sequence":"additional","affiliation":[{"name":"Research Scholar, SSR College of Pharmacy Sayli , Silvassa ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-0179","authenticated-orcid":false,"given":"Parixit","family":"Prajapati","sequence":"additional","affiliation":[{"name":"Department of Quality Assurance , , Silvassa ,","place":["India"]},{"name":"SSR College of Pharmacy Sayli , , Silvassa ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaimin","family":"Kumar Patel","sequence":"additional","affiliation":[{"name":"Navinta LLC , Mercer ,","place":["New Jersey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"1","key":"2025040112130823500_ref1","first-page":"57","article-title":"Elements of pharmacology","volume":"25","author":"Derasari","year":"1993","journal-title":"Indian Journal Of Pharmacology"},{"key":"2025040112130823500_ref2","author":"FDA","year":"2016"},{"issue":"1","key":"2025040112130823500_ref3","first-page":"12","article-title":"Unintended pregnancy and its adverse social and economic consequences on health system: A narrative review article","volume":"44","author":"Yazdkhasti","year":"2015","journal-title":"Iranian Journal of Public Health"},{"issue":"9","key":"2025040112130823500_ref4","first-page":"1510","article-title":"Quick and simple spectrophotometric method for estimation of ru486 in tablet dosage form","volume":"7","author":"Shah","year":"2018","journal-title":"World Journal of Pharmaceutical Research"},{"issue":"3","key":"2025040112130823500_ref5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.25004\/IJPSDR.2014.060316","article-title":"Quantitative determination of mifepristone in pharmaceutical samples by, visible spectrophotometric method using Ce (IV) as an analytical reagent","volume":"6","author":"Giri","year":"2014","journal-title":"International Journal of Pharmaceutical Science and Drug Research"},{"issue":"2","key":"2025040112130823500_ref6","first-page":"14","article-title":"Method development and validation of a visible spectrophotometric method for the assay of mifepristone in pharmaceuticial formulations using gold (III)","volume":"4","author":"Nagabhushana Reddy","year":"2014","journal-title":"International Journal of Drug Research and Technology"},{"key":"2025040112130823500_ref7","first-page":"120","article-title":"Analytical method development and validation for estimation of mifepristone in pure and pharmaceutical dosage form","volume":"33","author":"Modi","year":"2021","journal-title":"Journal of Pharmaceutical Research International"},{"issue":"2","key":"2025040112130823500_ref8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jchromb.2005.12.019","article-title":"An HPLC method for the determination of ng mifepristone in human plasma","volume":"832","author":"Guo","year":"2006","journal-title":"Journal of Chromatography B"},{"issue":"3","key":"2025040112130823500_ref9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.contraception.2007.04.004","article-title":"Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: Application to pharmacokinetic study","volume":"76","author":"Guo","year":"2007","journal-title":"Contraception"},{"issue":"1\u20132","key":"2025040112130823500_ref10","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jchromb.2007.06.016","article-title":"Simultaneous determination of rivanol and mifepristone in human plasma by a HPLC-UV method with solid-phase extraction","volume":"856","author":"Guo","year":"2007","journal-title":"Journal of Chromatography B."},{"issue":"1","key":"2025040112130823500_ref11","first-page":"1","article-title":"New stability indicating RP-HPLC-PDA method for determination of mifepristone in bulk and tablet formulation","volume":"7","author":"Khan","year":"2021","journal-title":"Future Journal of Pharmaceutical Science"},{"key":"2025040112130823500_ref12","first-page":"3","article-title":"Development and validation of stability indicating HPLC method for estimation of mifepristone","volume":"2","author":"Chavan","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"2025040112130823500_ref13","first-page":"13","article-title":"Development and validation of stability indicating HPTLC method for estimation of mifepristone","volume":"4","author":"Chavan","year":"2015","journal-title":"International Journal of Pharma Research & Review"},{"issue":"9","key":"2025040112130823500_ref14","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s10337-019-03758-1","article-title":"Detection of illegal abortion-induced drugs using rapid and simultaneous method for the determination of abortion-induced compounds by LC\u2013MS\/MS","volume":"82","author":"Lee","year":"2019","journal-title":"Chromatographia"},{"key":"2025040112130823500_ref15","article-title":"LC-MS\/MS method development and validation of mifepristone and its metabolites in human plasma","author":"Muhammed Rafsal","journal-title":"Der Pharmacia Sinica"},{"issue":"5\u20136","key":"2025040112130823500_ref16","first-page":"497","article-title":"Quantitative analysis of RU38486 (mifepristone) by HPLC triple quadrupole mass spectrometry","volume":"877","author":"Homer","year":"2009","journal-title":"Journal of Chromatography"},{"issue":"31","key":"2025040112130823500_ref17","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1039\/D4AY00546E","article-title":"A validated HPLC-MS\/MS method for the quantification of systemic mifepristone after subcutaneous application in mice","volume":"16","author":"Tevini","year":"2024","journal-title":"Analytical Methods"},{"key":"2025040112130823500_ref18","volume-title":"Validation of analytical procedures: Text and methodology","author":"ICH guideline, Q2 (R1)","year":"2005"},{"key":"2025040112130823500_ref19","volume-title":"Center for Drug Evaluation and Research. Reviewer guidance: Validation of chromatographic methods","author":"Food and Drug Administration","year":"1994"},{"key":"2025040112130823500_ref20","first-page":"1","volume-title":"QIA (R2), international conference on harmonization","author":"Guideline","year":"2003"}],"container-title":["Journal of Chromatographic Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/4\/bmaf017\/62828848\/bmaf017.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/chromsci\/article-pdf\/63\/4\/bmaf017\/62828848\/bmaf017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T08:16:50Z","timestamp":1743495410000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/chromsci\/article\/doi\/10.1093\/chromsci\/bmaf017\/8102312"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3,27]]}},"URL":"https:\/\/doi.org\/10.1093\/chromsci\/bmaf017","relation":{},"ISSN":["0021-9665","1945-239X"],"issn-type":[{"value":"0021-9665","type":"print"},{"value":"1945-239X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,3,27]]},"article-number":"bmaf017"}}